Page 6 - Mitchell Steiner News Today

Biotech company Veru announced Tuesday that the results of a COVID-19 treatment trial indicate that one of the firm's anti-cancer treatments was effective in reducing the risk of death among coronavirus patients.

Veru (NASDAQ: VERU), an Oncology Biopharmaceutical Company, skyrocketed to double digits after reporting beneficial data regarding a cancer drug that could also fight Covid-19.

Stock futures dip as Wall Streets rally to records is set to take a breather (SPY -0.2%). The biggest premarket movers: Coty, Take-Two Interactive, Chegg. Here is the current market situation from CNN Money European markets are mixed. The CAC 40 is higher by 0.47%, while the DAX is leading the FTSE 100 lower. They are down 0.42% and 0.03% respectively. What Is Moving the Markets Here are the headlines moving the markets. The Oil Deal That Could Destroy Iraq From Within The new Biden Administ...

Veru Announces Nature Medicine Publication Demonstrating that Enobosarm, an Androgen Receptor Targeted Agent, Inhibits Hormone Receptor Positive Metastatic Breast Cancer that has Become Resistant to Estrogen Receptor Targeted Endocrine and CDK4/6 Inhibitor Therapies January 19, 2021 08:30 ET | Source: Veru Inc. Veru Inc. Miami, Florida, UNITED STATES --International Study Establishes the Role of Androgen Receptor as a Tumor Suppressor in ER+ Advanced...

Biotech Verus Treatment Could Be a Game Changer, but What About the Stock? Lets check out the charts of this biotech name. Stocks quotes in this article: VERU For his second "Executive Decision" segment of Mad Money Monday evening, Jim Cramer spoke with Dr. Mitchell Steiner, chairman, president and CEO of Veru (VERU) , a biotech leading a charge against breast and prostate cancer. Steiner explained that Verus goal is to change the standard of care for patien...

Estrogen receptor (ER) is present in 85% of all breast cancers, and more than 90% of ER+ positive breast cancers also contain the AR which has been demonstrated to be an important therapeutic target in ER+ breast cancer. Enobosarm is an oral drug that selectively targets the AR in breast cancer without having the unwanted virilizing androgen adverse side effects including facial hair, acne, increase in hematocrit, or liver toxicity, while having potential clinical benefits including increasing ...